30
CARDIOVASCULAR
hamburger
Built for Patient Impact | Innovation Results


Our shared purpose — changing the course of heart failure. Your purpose is to maintain a healthy rhythm for your patients and provide peace of mind. Abbott’s ICDs and CRT-Ds are built with our exclusive algorithms proven to deliver better patient outcomes. It is this type of innovation that drives us at Abbott making it possible to deliver personalized therapy and restore quality of life.

Keep to the beat of your patients' Rhythm with SyncAV™ CRT Technology

Pulse

Advancing a patient to the next level of CRT response is associated with decreased mortality rates, reduced heart failure events and a decrease in healthcare expenditures.1,2 Dynamically adjust AV delays based on your patients’ intrinsic conduction and deliver improved electrical synchrony and narrower QRS1,2 with SyncAV CRT Technology.

Longer Patient Survival with SyncAV CRT Technology


in a study published by the JAHA were shown to have a narrower QRS duration when SyncAV CRT technology was optimized2

100% of patients

QRS narrowing after CRT implantation associated with over 2x lower mortality rate in patients with LBBB4

Other Patient Outcomes

34% reduction in all-cause hospitalization readmissions3

30% reduction in cumulative heart failure hospitalizations3

23% reduction ($1,135) in 2-year cost3

$4,031 lifetime savings per CRT patient3

100% of patients

41%
reduction

in heart failure readmissions3

VF Therapy Assurance Can Make a Life-Changing Difference

Time

Every patient deserves access to transformative therapy. VF Therapy Assurance is designed to seamlessly integrate into your patients’ day-to-day lives. It’s Abbott’s unique discriminator that allows you to achieve enhanced detection and treatment of challenging ventricular arrhythmias.

Enhanced Detection and Treatment with VF Therapy Assurance


who received HV therapy due to VFTA who would have been otherwise untreated for potentially life-threatening arrhythmias5

86% of patients

>800 PATIENTS
annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance.6

DeFT Response™ Technology Delivers the Power of Customization

Customize

Non-invasive programming options make it possible to rapidly optimize therapy performance to each patient’s unique needs. DeFT Response Technology is the industry’s most flexible option for management of DFTs. Lower DFTs7 and customize the matching of shock waveform to your patients’ cellular response times.

Safer Management of Care with DeFT Response Technology



in preserving a 10J safety margin with DeFT Response Technology vs. 83% achievement of 10J safety margin in fixed-tilt group of patients with competitive devices.7

100% success


Implant Today. 1.5T and 3T MRI Ready Tomorrow.

MR

NO WAITING FOR MRI SCANS

Abbott’s 1.5T and 3T MRI ready solutions* ensure no loss of CRT therapy for your patients during full-body scans and allows for programming of an MRI timeout

READY TO MAKE A CHANGE IN HEART FAILURE?

Contact your Abbott Sales Representative


FPO scan code

Scan this QR code to read on your tablet

* For additional information about specific MR Conditional ICDs and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to the Abbott MRI Ready Systems Manual at medical.abbott/manuals

 

References:

  1. Wisnoskey BJ, Cranke G, Cantillon DJ, and Varma N. “Feasibility of Device-Based Electrical Optimization via Application of the Negative AV Hysteresis Algorithm during Cardiac Resynchronization Therapy (CRT).” Heart Rhythm. 2016; 13 (5S): S443.
  2. Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489.http://jaha.ahajournals.org/content/7/3/e007489. Accessed April 17, 2018.
  3. Varma, N., Hu, Y., Connolly, A. T., Thibault, B., Singh, B., Mont, L., … & Zareba, W. (2021). Gain in realworld cardiac resynchronization therapy efficacy with SyncAV dynamic optimization: Heart failure hospitalizations and costs. Heart Rhythm.
  4. Jastrzebski M, Baranchuk A, Fijorek K, Kisiel R, Kukla P, Sondej T, Czarnecka D. Cardiac resynchronization therapy-induced acute shortening of QRS duration predicts long-term mortality only in patients with left bundle branch block. Europace. 2019 Feb 1;21(2):281-289. doi: 10.1093/europace/euy254. PMID: 30403774.
  5. Based on over 560,000 episodes (20,000 patients). Performance of VF Therapy Assurance Feature. Abbott Clinical Summary.
  6. Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).
  7. Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71.

MAT-2112854 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.